ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Too Few Minority Scientists Enter Careers In Public Health, Oncology, Bynum Reports

March 24, 1989

The Meeting At the Beverly Hills Suite: Salick, Zeneca Par Way Acrimoniously

May 2, 1997

President’s Budget Asks Increase of 8.5 Percent For NCI In FY 1989; Still No Construction Money

February 26, 1988

Clearinghouse Insists On New Dichlorvos Test; CSWG Disagrees

March 24, 1978

Virology Contract Phaseout To Cut $5 Million In FY 1980; Bigger reduction Coming In 1982

July 27, 1979

Four CIDAC Contracts Will Go To Cancer Research Centers; RFPs To Be Released January or February

December 20, 1974